Interferon-gamma priming is involved in the activation of arginase by oligodeoxinucleotides containing CpG motifs in murine macrophages.
Recognition of microbial products by macrophages (Mphi) stimulates an inflammatory response and plays a critical role in directing the host immune response against infection. In the present work, we showed for the first time that synthetic oligodeoxynucleotides containing unmethylated cytosine guanine motifs (CpG) are able to stimulate, in the presence of interferon-gamma (IFN-gamma), both arginase and inducible nitric oxide synthase (iNOS) in murine Mphi. Unexpectedly, IFN-gamma, a cytokine believed to be an inhibitor of arginase activity, intervened in the activation of this enzyme. A significant increase in arginase activity was observed upon a short pre-incubation (1 hr) with IFN-gamma and subsequent CpG stimulation. Therefore, a very interesting observation of this study was that the CpG-mediated arginase activity is dependent on IFN-gamma priming. The increase in arginase activity as a result of stimulation with CpG plus IFN-gamma was correlated with augmented expression of the arginase II isoform. The use of pharmacological specific inhibitors revealed that arginase activity was dependent on p38 mitogen-activated protein kinase (MAPK) and extracellular signal-regulated protein kinase (ERK), but independent of c-Jun N-terminal kinase (JNK) activation. This report reveals a singular effect of the combination of CpG and IFN-gamma, one of the mayor cytokines produced in response to CpG administration in vivo.
Liscovsky
Miriam V
MV
Departamento de Bioquímica Clínica, CIBICI (CONICET), Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.
Ranocchia
Romina P
RP
Gorlino
Carolina V
CV
Alignani
Diego O
DO
Morón
Gabriel
G
Maletto
Belkys A
BA
Pistoresi-Palencia
María C
MC
D000818:Animals; D000873:Anthracenes / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology; D001119:Arginase / Q000096:biosynthesis*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors / Q000276:immunology / Q000378:metabolism; D005260:Female; D005419:Flavonoids / Q000494:pharmacology; D020862:GC Rich Sequence / Q000276:immunology*; D007093:Imidazoles / Q000494:pharmacology; D007371:Interferon-gamma / Q000494:pharmacology*; D016753:Interleukin-10 / Q000276:immunology; D018664:Interleukin-12 / Q000276:immunology; D048031:JNK Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D008264:Macrophages / Q000187:drug effects* / Q000201:enzymology; D051379:Mice; D008807:Mice, Inbred BALB C; D052247:Nitric Oxide Synthase Type II / Q000187:drug effects / Q000378:metabolism; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology; D015854:Up-Regulation; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism
D000873:Anthracenes; D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D005419:Flavonoids; D007093:Imidazoles; D008070:Lipopolysaccharides; D009838:Oligodeoxyribonucleotides; D011725:Pyridines; D016753:Interleukin-10; D018664:Interleukin-12; C432165:pyrazolanthrone; D007371:Interferon-gamma; D052247:Nitric Oxide Synthase Type II; D048049:Extracellular Signal-Regulated MAP Kinases; D048031:JNK Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases; C481673:Arg2 protein, mouse; D001119:Arginase; C093642:SB 203580; C093973:2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
Eur J Immunol. 1999 Oct;29(10):3390-400
10540351
J Immunol. 2008 Apr 1;180(7):4523-9
18354174
J Immunol. 2000 Nov 1;165(9):5153-60
11046047
J Biol Chem. 2001 May 11;276(19):15881-5
11278602
J Immunol. 2001 Jun 15;166(12):7082-9
11390452
Nat Immunol. 2001 Oct;2(10):907-16
11577346
J Immunol. 2001 Dec 1;167(11):6533-44
11714822
FEMS Immunol Med Microbiol. 2001 Dec;32(1):65-71
11750224
Annu Rev Immunol. 2002;20:709-60
11861616
Trends Immunol. 2002 Feb;23(2):96-101
11929133
J Immunol. 2002 May 1;168(9):4711-20
11971021
Microbes Infect. 2002 Jul;4(9):903-14
12106783
J Immunol. 2002 Sep 1;169(5):2253-63
12193690
Clin Diagn Lab Immunol. 2002 Nov;9(6):1260-9
12414759
Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4843-8
12655043
Science. 2003 Jun 6;300(5625):1524-5
12791976
Int Immunopharmacol. 2003 Sep;3(9):1247-55
12890422
Nat Immunol. 2004 Feb;5(2):190-8
14716310
J Leukoc Biol. 2004 Feb;75(2):163-89
14525967
Mol Genet Metab. 2004 Apr;81 Suppl 1:S38-44
15050972
J Immunol. 2004 Aug 1;173(3):2109-17
15265947
J Immunol. 1990 May 15;144(10):3877-80
2332635
FEBS Lett. 1991 Jul 22;285(2):194-8
1713174
Life Sci. 1994;55(10):797-805
7520966
J Immunol Methods. 1994 Sep 14;174(1-2):231-5
8083527
Biochem Biophys Res Commun. 1995 Jan 17;206(2):667-73
7530004
Eur J Immunol. 1995 Apr;25(4):1101-4
7537672
Biochem Biophys Res Commun. 1995 May 25;210(3):1009-16
7539253
J Biol Chem. 1997 Feb 7;272(6):3689-93
9013624
Gen Pharmacol. 1997 Aug;29(2):159-66
9251894
J Interferon Cytokine Res. 1997 Dec;17(12):781-8
9452366
Am J Physiol. 1998 Jan;274(1 Pt 2):H342-8
9458885
J Interferon Cytokine Res. 1998 Apr;18(4):263-71
9568729
J Immunol. 1998 Oct 15;161(8):3930-5
9780160
Am J Physiol. 1998 Nov;275(5 Pt 1):E740-7
9814991
J Biochem. 1999 Mar;125(3):586-93
10050048
J Cell Biol. 1999 Feb 8;144(3):427-34
9971738
J Immunol. 1999 Jul 1;163(1):224-31
10384120
J Leukoc Biol. 2005 Jun;77(6):898-905
15758079
J Immunol. 2005 Nov 1;175(9):5601-5
16237046
Clin Immunol. 2005 Dec;117(3):251-61
16182607
Eur J Immunol. 2006 Jan;36(1):12-20
16323249
Nat Immunol. 2006 Apr;7(4):375-81
16491077
Nat Rev Drug Discov. 2006 Jun;5(6):471-84
16763660
Immunobiology. 2006;211(6-8):511-24
16920490
J Interferon Cytokine Res. 2006 Dec;26(12):893-900
17238832
Infect Immun. 2000 Aug;68(8):4653-7
10899869